James Johnson, MD
Professor of Medicine
James R. Johnson, M.D. is a Professor of Medicine and Senior Associate Director of the Infectious Diseases Fellowship Program and the VA Molecular Epidemiology Unit. Dr. Johnson received his training in internal medicine and infectious diseases at the University of Washington in Seattle. His research interests include: 1) molecular pathogenesis of urinary tract infections, with an emphasis on the virulence properties, ecology, and phylogenetic aspects of uropathogenic E. coli, 2) molecular epidemiology of antibiotic resistance in E. coli, and 3) virulence factors and molecular epidemiology of enterococci, including VRE.
- Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, Kuskowski MA, Tchesnokova V, Sokurenko EV, Johnson JR, VICTORY Investigators. Escherichia coli sequence type 131 (ST131) as an emergent multidrug-resistant pathogen among U.S. veterans. Clin Infect Dis 2013;57:1256-65. PMID: 23926176.
- Johnson JR, Russo TA, Drawz SM, Clabots C, Olson R, Rosen H. OxyR contributes to the virulence of a clonal group A Escherichia coli strain (O17:K+:H18) in animal models of urinary tract infection, subcutaneous infection, and systemic sepsis. Microb Pathog 2013;64:1-5. PMID: 23850958.
- Johnson JR, Drawz SM, Porter S, Kuskowski MA. Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and co-resistance phenotype among recent Escherichia coli isolates from U.S. veterans. Antimicrob Agents Chemother 2013;57:4856-60. PMID: 23877695.
- Banerjee R, Johnston B, Lohse C, Chattopadhyay S, Tchesnokova V, Sokurenko EV, Johnson JR. The clonal distribution and diversity of extraintestinal Escherichia coli varies according to patient characteristics. Antimicrob Agents Chemother 2013;57:5912-7. PMID: 24041881.
- Banerjee R, Robicsek A, Kuskowski M, Porter S, Johnston B, Sokurenko E, Tchesnokova V, Price L, Johnson JR. Molecular epidemiology of Escherichia coli sequence type ST131 and its H30 and H30-Rx subclones among extended-spectrum beta-lactamase-positive and -negative E. coli clinical isolates from the Chicago region (2007-2010). Antimicrob Agents Chemother 2013;57:6385-8. PMID: 24080662.
- Price LB*, Johnson JR* (*equal contributors), Aziz M, Clabots C, Johnston B, Tchesnokova V, Nordstrom L, Billig M, Chattopadhyay S, Stegger M, Andersen PS, Pearson T, Riddell K, Rogers P, Scholes D, Kahl B, Keim P, Sokurenko EV. The epidemic of ESBL-producing Escherichia coli ST131 is driven by a single highly virulent subclone, H30-Rx. mBio 2013;6:e00377-13.
- Drekonja DM, Gnadt C, Kuskowski MA, Johnson JR. Urine cultures among hospitalized veterans: casting too broad a net? Infect Control Hosp Epidemiol (in press).